Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) have been assigned an average rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $7.77.
Several research analysts have issued reports on PACB shares. UBS Group reduced their price objective on Pacific Biosciences of California from $12.50 to $12.00 and set a “buy” rating on the stock in a report on Friday, February 16th. Scotiabank decreased their price target on Pacific Biosciences of California from $15.00 to $8.00 and set a “sector outperform” rating on the stock in a report on Thursday, April 18th. Barclays dropped their price objective on Pacific Biosciences of California from $8.00 to $3.00 and set an “equal weight” rating for the company in a report on Wednesday, April 10th. Sanford C. Bernstein reduced their target price on shares of Pacific Biosciences of California from $9.00 to $2.50 and set an “outperform” rating on the stock in a research note on Thursday, April 18th. Finally, StockNews.com raised shares of Pacific Biosciences of California to a “sell” rating in a research note on Wednesday, April 17th.
Read Our Latest Stock Analysis on Pacific Biosciences of California
Insider Buying and Selling at Pacific Biosciences of California
Institutional Investors Weigh In On Pacific Biosciences of California
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kayne Anderson Rudnick Investment Management LLC acquired a new position in Pacific Biosciences of California during the third quarter worth approximately $59,000. Private Wealth Partners LLC acquired a new stake in shares of Pacific Biosciences of California during the 4th quarter worth about $98,000. First Trust Direct Indexing L.P. bought a new position in shares of Pacific Biosciences of California during the first quarter worth approximately $98,000. Raymond James Financial Services Advisors Inc. bought a new stake in Pacific Biosciences of California in the 3rd quarter valued at $105,000. Finally, Carret Asset Management LLC grew its stake in shares of Pacific Biosciences of California by 52.4% in the first quarter. Carret Asset Management LLC now owns 32,000 shares of the biotechnology company’s stock valued at $120,000 after acquiring an additional 11,000 shares in the last quarter.
Pacific Biosciences of California Stock Performance
Pacific Biosciences of California stock opened at $1.56 on Tuesday. Pacific Biosciences of California has a 12-month low of $1.25 and a 12-month high of $14.55. The stock has a 50-day simple moving average of $4.05 and a 200 day simple moving average of $6.54. The company has a quick ratio of 7.21, a current ratio of 7.81 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $418.01 million, a price-to-earnings ratio of -1.29 and a beta of 1.83.
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) last announced its earnings results on Thursday, February 15th. The biotechnology company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. The company had revenue of $58.36 million during the quarter, compared to the consensus estimate of $57.96 million. Pacific Biosciences of California had a negative net margin of 152.97% and a negative return on equity of 40.23%. The company’s revenue was up 113.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.35) earnings per share. On average, research analysts anticipate that Pacific Biosciences of California will post -1.01 earnings per share for the current fiscal year.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
Further Reading
- Five stocks we like better than Pacific Biosciences of California
- Russell 2000 Index, How Investors Use it For Profitable Trading
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- Earnings Per Share Calculator: How to Calculate EPS
- Merger or Not, Albertson’s Companies is a Good Buy
- How to invest in marijuana stocks in 7 steps
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.